Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
 Annual Meeting - EconoTimes)
EAGAN, Minn., March 27, 2017 -- Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research.
Poster Presentations:
| Session Date & Time: | Monday, April 3, 8:00 AM - 12:00 PM Eastern Time | ||||||||||
| Topic Track: | Immunology | ||||||||||
| Session: | Adaptive Immunity to Cancer | ||||||||||
| Presentation Title: | A novel tumor vaccine platform: direct conjugation of antigens to the β-glucan PAMP Imprime PGG enhances antigen presentation and T cell priming | ||||||||||
| Session Location: | Poster Section 29 | ||||||||||
| Poster Board Number: | 22 | ||||||||||
| Abstract #: | 1703 | ||||||||||
| Session Date & Time: | Tuesday, April 4, 8:00 AM - 12:00 PM Eastern Time | ||
| Topic Track: | Immunology | ||
| Session: | Late-Breaking Research: Immunology | ||
| Presentation Title: | Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies | ||
| Session Location: | Poster Section 35 | ||
| Poster Board Number: | 22 | ||
| Abstract #: | LB-199 |
| Session Date & Time: | Tuesday, April 4, 8:00 AM - 12:00 PM Eastern Time | ||
| Topic Track: | Immunology | ||
| Session: | Inflammation in the Tumor Microenvironment | ||
| Presentation Title: | Imprime PGG, a novel innate immune therapeutic in phase 2 clinical development, induces mobilization of monocytes and focalized recruitment of innate immune cells to tumor sites | ||
| Session Location: | Poster Section 28 | ||
| Poster Board Number: | 1 | ||
| Abstract #: | 3688 |
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA® in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact: David Walsh Communications Biothera Pharmaceuticals, Inc. 651-256-4606 [email protected]
